Cytokinetics to Participate in Upcoming Investor Conferences
February 03 2016 - 4:00PM
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Robert I.
Blum, President and Chief Executive Officer, is scheduled to
present at the 18th Annual BIO CEO & Investor Conference on
Monday, February 8, 2016 at 1:30 PM EST at the Waldorf Astoria in
New York, NY. Members of Cytokinetics' senior management team will
also participate in the SunTrust Robinson Humphrey 2016 Orphan Drug
Day on Tuesday, February 23, 2016 at the JW Marriott Essex House in
New York, NY.
Interested parties may access the live webcast
of the BIO CEO presentation by visiting the Investors & Media
section of the Cytokinetics website at www.cytokinetics.com. The
webcast replay of the presentation will be archived on the
Presentations page within the Investors & Media section of
Cytokinetics' website until May 8, 2016.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators as potential treatments for
debilitating diseases in which muscle performance is compromised
and/or declining. As a leader in muscle biology and the mechanics
of muscle performance, the company is developing small molecule
drug candidates specifically engineered to increase muscle function
and contractility. Cytokinetics’ lead drug candidate is tirasemtiv,
a fast skeletal muscle activator, for the potential treatment of
ALS. Tirasemtiv has been granted orphan drug designation and fast
track status by the U.S. Food and Drug Administration and orphan
medicinal product designation by the European Medicines Agency for
the potential treatment of ALS. Cytokinetics retains the right to
develop and commercialize tirasemtiv. Cytokinetics is collaborating
with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac
muscle activator, for the potential treatment of heart failure.
Cytokinetics is collaborating with Astellas Pharma Inc. to develop
CK-2127107, a fast skeletal muscle activator, for the potential
treatment of spinal muscular atrophy. Amgen holds an exclusive
license worldwide to develop and commercialize omecamtiv mecarbil
and Astellas holds an exclusive license worldwide to develop and
commercialize CK-2127107. Both licenses are subject to
Cytokinetics’ specified development and commercialization
participation rights. For additional information about
Cytokinetics, visit www.cytokinetics.com.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024